In this episode (20:20), Medicom’s correspondent covers 6 presentations from the European Alliance of Associations for Rheumatology (EULAR 2022) annual meeting, held on-site in Copenhagen and virtual live from 1-4 June 2022, marking EULAR’s 75th anniversary!
The topics discussed are:
- JAK inhibitor shows to be effective in non-radiographic axSpA
Once-daily therapy with upadacitinib led to an Assessment of SpondyloArthritis International Society 40 (ASAS40) response in 45% of patients with active, non-radiographic axial spondylarthritis (nr-axSpA) at week 14 in the SELECT-AXIS-2 trial. This was the first phase 3 trial data of JAK inhibitors ever presented in this indication.
- Baricitinib shows great potential in juvenile idiopathic arthritis
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares. These occurred in more than half of the cases in the placebo group but only about 17% in the baricitinib group.
- TYK2 inhibition: A rising star in lupus therapy?
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial. Depending on the dosage, up to 58.2% of study drug recipients showed a Systemic Lupus Erythematosus Responder Index (SRI) 4 response, significantly more than on placebo.
- Antifibrotic therapy effective in patients with negative prognostic factors for lung function decline
Previously, nintedanib has shown to slow lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial. A post-hoc analysis of this trial revealed that treatment benefit is also evident in patients with 4 characteristics associated with a fast decline in lung function.
- Treatment with bimekizumab beneficial in psoriatic arthritis
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a therapy for psoriatic arthritis (PsA). At week 16, over 40% of study participants reached an ACR50 response.
- IL-6 inhibition successful in treating polymyalgia rheumatica
Sarilumab demonstrated positive results in the randomised, phase 3 SAPHYR trial for patients with polymyalgia rheumatica (PMR). Significantly more participants reached sustained remission and the risk of flares was reduced.
Copyright ©2021 Medicom Medical Publishers
« Enzalutamide with active surveillance reduces prostate-cancer progression Next Article
Consensus on isotretinoin laboratory monitoring in acne treatment »